Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT03539055
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT03539055
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03539055. Allocation not applicable; no masking; primary purpose prevention. Start 2018-09-01 (actual); primary completion 2023-12-31 (actual). Results posted on 2025-06-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
- Acronym
- DEA-LAA
- Condition
- Atrial Fibrillation
- Condition
- Device Related Thrombus
- Condition
- Left Atrial Appendage Thrombosis
- Condition
- Watchman LAA Closure Device
- Intervention (Drug)
- Dabigatran Etexilate Oral Capsule
- Lead sponsor
- Vanderbilt University Medical Center
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct03539055- Content hash
bda88d59df2ade29649db2dadbe9b6e00cc0838d4f45bfeb56d37d882433b230